



October 24, 2011

Dr. Janet Woodcock
Director, Center for Drug Evaluation and Research
Food & Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993

Dear Dr. Woodcock,

The Obesity Care Continuum (OCC) appreciates the continued dialogue you have engaged in with our organizations and would like to take this opportunity to offer our support and expertise. Now that Vivus has resubmitted its New Drug Application (NDA) for Qnexa to include a contraindication for women of childbearing potential as well as the company's proposed Risk Evaluation and Mitigation Strategy (REMS), it appears that the FDA will be pulling together another Advisory Committee to review the company's resubmission. The members of the OCC believe it would be helpful to the Center for Drug Evaluation and Research (CDER) if we shared with you and your staff the list of suggested experts for future obesity drug Advisory Committee meetings, previously provided during our last face-to-face meeting on July 18th.

Again, we appreciate the opportunity to continue this open dialogue with you and the CDER as we work together toward establishing a review and approval process, which is informed by the top experts in the field of obesity treatment. Should you have any questions, please feel free to contact us through OCC Washington Coordinator Chris Gallagher at chris@potomaccurrents.com or via telephone at 571-235-6475.


Sincerely,

A handwritten signature in black ink that reads "Robin Blackstone, MD, FACS".

Robin Blackstone, MD, FASMBS, FACS
ASMBS President
Scottsdale, Arizona

A handwritten signature in black ink that reads "Sylvia Escott-Stump".

Sylvia Escott-Stump, MA, RD, LDN
ADA President, 2011-2012
Winterville, North Carolina



A handwritten signature in black ink, appearing to read "Patrick O'Neil".


Patrick O'Neil
TOS, President, 2011-2012
Charleston, SC

A handwritten signature in black ink, appearing to read "Barbara Thompson".

Barbara Thompson
OAC Chair of Board of Directors
Pittsburgh, Pennsylvania

With a combined membership of over 100,000 healthcare professionals and patient advocates, the Obesity Care Continuum is dedicated to promoting access to, and coverage of, the continuum of care surrounding the treatment of overweight and obesity. The OCC also challenges weight bias and stigma oriented policies – whenever and wherever they occur. The OCC is a coalition of the Obesity Action Coalition (OAC), the Obesity Society (TOS), the American Dietetic Association (ADA), and the American Society for Metabolic and Bariatric Surgery (ASMBS).

Attachment: Suggested Experts in the Obesity Field for Future FDA Advisory Committees



The Obesity Care Continuum

Suggested Experts in the Obesity Field for Future FDA Advisory Committees Evaluating New Obesity Drugs

Richard Bergman
Robert Berkowitz
Dan Bessesen
Charles Billington
Martin Binks
Claude Bouchard
Philip Brantley
Scott Butsch
Lawrence Cheskin
Jeanne Clark
Barbara Corkey
William Donahoo
Andrea Dunaif
Nikhil Durhandar
Andrew Greenberg
Barbara Hansen
Donald Hensrud
Michael Jensen

Scott Kahan
Lee Kaplan
Ahmed Kissebeh
Ron Krauss
Ed Livingston
Corby Martin
Cathy Nonas
Michael Perri
Walter Pories
Rebecca Puhl
Phil Schauer
Melinda Sothern
Adam Tsai
Gabriel Uwaifo
David West
Donald Williamson
Susan Yanovski
Jack Yanovski